{"id":36894,"date":"2025-07-08T14:06:13","date_gmt":"2025-07-08T06:06:13","guid":{"rendered":"https:\/\/flcube.com\/?p=36894"},"modified":"2025-07-08T14:06:14","modified_gmt":"2025-07-08T06:06:14","slug":"gsk-completes-acquisition-of-boston-pharmas-bp-asset-ix-for-efimosfermin-alpha","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36894","title":{"rendered":"GSK Completes Acquisition of Boston Pharma’s BP Asset IX for Efimosfermin Alpha"},"content":{"rendered":"\n

UK-based GlaxoSmithKline (GSK; NYSE: GSK<\/a>)\u00a0announced the completion of its acquisition of BP Asset IX, a subsidiary of US-based Boston Pharmaceuticals. The deal includes the investigational drug efimosfermin alfa, a potentially best-in-class, long-acting FGF21 analog currently in Phase III development for steatotic liver disease (SLD), including metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-associated liver disease (ALD).<\/p>\n\n\n\n

Drug Profile and Mechanism<\/strong>
Efimosfermin is designed as a once-monthly subcutaneous injectable FGF21 variant. It works by modulating key metabolic pathways to reduce liver fat, improve hepatic inflammation, and potentially reverse fibrosis in MASH patients. The drug is currently being evaluated in clinical trials for moderate-to-advanced fibrosis, including cirrhosis.<\/p>\n\n\n\n

Market Potential and Combination Therapy<\/strong>
GSK believes efimosfermin could address significant unmet needs in advanced liver disease. The company is also exploring the potential combination use of efimosfermin with its siRNA therapy GSK’990, which targets other SLD patient subgroups.<\/p>\n\n\n\n

Financial Details<\/strong>
The total cash consideration for the acquisition amounts to USD 2 billion. This includes an upfront payment of USD 1.2 billion and up to USD 800 million in success-based milestones. GSK will also assume responsibility for milestone payments and tiered royalties owed to Novartis. The company plans to commercially launch efimosfermin by 2029.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

UK-based GlaxoSmithKline (GSK; NYSE: GSK)\u00a0announced the completion of its acquisition of BP Asset IX, a…<\/p>\n","protected":false},"author":1,"featured_media":36897,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4071,278,184,914],"class_list":["post-36894","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-boston-pharmaceuticals","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk"],"yoast_head":"\nGSK Completes Acquisition of Boston Pharma's BP Asset IX for Efimosfermin Alpha - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-based GlaxoSmithKline (GSK; NYSE: GSK)\u00a0announced the completion of its acquisition of BP Asset IX, a subsidiary of US-based Boston Pharmaceuticals. The deal includes the investigational drug efimosfermin alfa, a potentially best-in-class, long-acting FGF21 analog currently in Phase III development for steatotic liver disease (SLD), including metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-associated liver disease (ALD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36894\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Completes Acquisition of Boston Pharma's BP Asset IX for Efimosfermin Alpha\" \/>\n<meta property=\"og:description\" content=\"UK-based GlaxoSmithKline (GSK; NYSE: GSK)\u00a0announced the completion of its acquisition of BP Asset IX, a subsidiary of US-based Boston Pharmaceuticals. The deal includes the investigational drug efimosfermin alfa, a potentially best-in-class, long-acting FGF21 analog currently in Phase III development for steatotic liver disease (SLD), including metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-associated liver disease (ALD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36894\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-08T06:06:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-08T06:06:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0807.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36894#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36894\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK Completes Acquisition of Boston Pharma’s BP Asset IX for Efimosfermin Alpha\",\"datePublished\":\"2025-07-08T06:06:13+00:00\",\"dateModified\":\"2025-07-08T06:06:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36894\"},\"wordCount\":211,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36894#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0807.webp\",\"keywords\":[\"Boston Pharmaceuticals\",\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36894#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36894\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36894\",\"name\":\"GSK Completes Acquisition of Boston Pharma's BP Asset IX for Efimosfermin Alpha - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36894#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36894#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0807.webp\",\"datePublished\":\"2025-07-08T06:06:13+00:00\",\"dateModified\":\"2025-07-08T06:06:14+00:00\",\"description\":\"UK-based GlaxoSmithKline (GSK; NYSE: GSK)\u00a0announced the completion of its acquisition of BP Asset IX, a subsidiary of US-based Boston Pharmaceuticals. The deal includes the investigational drug efimosfermin alfa, a potentially best-in-class, long-acting FGF21 analog currently in Phase III development for steatotic liver disease (SLD), including metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-associated liver disease (ALD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36894#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36894\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36894#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0807.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0807.webp\",\"width\":1080,\"height\":608,\"caption\":\"GSK Completes Acquisition of Boston Pharma's BP Asset IX for Efimosfermin Alpha\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36894#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK Completes Acquisition of Boston Pharma’s BP Asset IX for Efimosfermin Alpha\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK Completes Acquisition of Boston Pharma's BP Asset IX for Efimosfermin Alpha - Insight, China's Pharmaceutical Industry","description":"UK-based GlaxoSmithKline (GSK; NYSE: GSK)\u00a0announced the completion of its acquisition of BP Asset IX, a subsidiary of US-based Boston Pharmaceuticals. The deal includes the investigational drug efimosfermin alfa, a potentially best-in-class, long-acting FGF21 analog currently in Phase III development for steatotic liver disease (SLD), including metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-associated liver disease (ALD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36894","og_locale":"en_US","og_type":"article","og_title":"GSK Completes Acquisition of Boston Pharma's BP Asset IX for Efimosfermin Alpha","og_description":"UK-based GlaxoSmithKline (GSK; NYSE: GSK)\u00a0announced the completion of its acquisition of BP Asset IX, a subsidiary of US-based Boston Pharmaceuticals. The deal includes the investigational drug efimosfermin alfa, a potentially best-in-class, long-acting FGF21 analog currently in Phase III development for steatotic liver disease (SLD), including metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-associated liver disease (ALD).","og_url":"https:\/\/flcube.com\/?p=36894","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-08T06:06:13+00:00","article_modified_time":"2025-07-08T06:06:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0807.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36894#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36894"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK Completes Acquisition of Boston Pharma’s BP Asset IX for Efimosfermin Alpha","datePublished":"2025-07-08T06:06:13+00:00","dateModified":"2025-07-08T06:06:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36894"},"wordCount":211,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36894#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0807.webp","keywords":["Boston Pharmaceuticals","GlaxoSmithKline","GSK","NYSE: GSK"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36894#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36894","url":"https:\/\/flcube.com\/?p=36894","name":"GSK Completes Acquisition of Boston Pharma's BP Asset IX for Efimosfermin Alpha - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36894#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36894#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0807.webp","datePublished":"2025-07-08T06:06:13+00:00","dateModified":"2025-07-08T06:06:14+00:00","description":"UK-based GlaxoSmithKline (GSK; NYSE: GSK)\u00a0announced the completion of its acquisition of BP Asset IX, a subsidiary of US-based Boston Pharmaceuticals. The deal includes the investigational drug efimosfermin alfa, a potentially best-in-class, long-acting FGF21 analog currently in Phase III development for steatotic liver disease (SLD), including metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-associated liver disease (ALD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36894#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36894"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36894#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0807.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0807.webp","width":1080,"height":608,"caption":"GSK Completes Acquisition of Boston Pharma's BP Asset IX for Efimosfermin Alpha"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36894#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK Completes Acquisition of Boston Pharma’s BP Asset IX for Efimosfermin Alpha"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0807.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36894"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36894\/revisions"}],"predecessor-version":[{"id":36898,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36894\/revisions\/36898"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36897"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}